- Home
- MYGN vs SHEN Comparison
MYGN vs SHEN Comparison
Compare MYGN & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SHEN
- Stock Information
- Founded
- MYGN 1991
- SHEN 1902
- Country
- MYGN United States
- SHEN United States
- Employees
- MYGN N/A
- SHEN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SHEN Telecommunications Equipment
- Sector
- MYGN Health Care
- SHEN Telecommunications
- Exchange
- MYGN Nasdaq
- SHEN Nasdaq
- Market Cap
- MYGN 744.7M
- SHEN 673.1M
- IPO Year
- MYGN 1995
- SHEN N/A
- Fundamental
- Price
- MYGN $4.92
- SHEN $13.91
- Analyst Decision
- MYGN Hold
- SHEN Strong Buy
- Analyst Count
- MYGN 15
- SHEN 1
- Target Price
- MYGN $15.14
- SHEN $26.00
- AVG Volume (30 Days)
- MYGN 2.1M
- SHEN 290.9K
- Earning Date
- MYGN 08-05-2025
- SHEN 08-06-2025
- Dividend Yield
- MYGN N/A
- SHEN 0.72%
- EPS Growth
- MYGN N/A
- SHEN N/A
- EPS
- MYGN N/A
- SHEN N/A
- Revenue
- MYGN $831,300,000.00
- SHEN $346,708,000.00
- Revenue This Year
- MYGN N/A
- SHEN $13.32
- Revenue Next Year
- MYGN $6.68
- SHEN $7.77
- P/E Ratio
- MYGN N/A
- SHEN N/A
- Revenue Growth
- MYGN 7.38
- SHEN 27.84
- 52 Week Low
- MYGN $3.81
- SHEN $9.77
- 52 Week High
- MYGN $29.30
- SHEN $21.89
- Technical
- Relative Strength Index (RSI)
- MYGN 46.03
- SHEN 62.24
- Support Level
- MYGN $4.78
- SHEN $13.78
- Resistance Level
- MYGN $5.29
- SHEN $14.39
- Average True Range (ATR)
- MYGN 0.32
- SHEN 0.40
- MACD
- MYGN 0.11
- SHEN 0.08
- Stochastic Oscillator
- MYGN 60.98
- SHEN 72.77
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About SHEN Shenandoah Telecommunications Co
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.